Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (262)
  2. Journal Article (245)
  3. Review (26)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (573)
  2. Gastrointestinal Oncology Service (573)
  3. Solid Tumor Oncology Division (573)
  4. Center for Pancreatic Cancer Research (215)
  5. Epidemiology and Biostatistics (122)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (156)
  2. James Harding (130)
  3. William Jarnagin (66)
  4. Marinela Capanu (65)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (18)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (166)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (182)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (573)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition
    Journal Article

    Harding, J. J.; Lowery, M. A.; Shih, A. H.; Schvartzman, J. M.; Hou, S.; Famulare, C.; Patel, M.; Roshal, M.; Do, R. K.; Zehir, A.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Biomarker-driven and molecular targeted therapies for hepatobiliary cancers
    Journal Article

    Harris, W. P.; Wong, K. M.; Saha, S.; El Dika, I.; Abou-Alfa, G. K.
    Seminars in Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Waidmann, O.; Merle, P.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Harris, W. P.; Nemunaitis, J.; Olteanu, S.; Sarker, D.; Tan, B. R.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Meeting Abstract

    Waidmann, O.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Chen, Y. H.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A.; Parnis, F.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Rimassa, L.; Cicin, I.; Blanc, J. F.; Klümpen, H. J.; Zagonel, V.; Tran, A.; Kim, S.; Lin, Z. Z.; Tam, V. C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Abou-Alfa, G. K.; El-Khoueiry, A. B.; Meyer, T.; Rimassa, L.; Merle, P.; Chan, S. L.; Tran, A.; Parnis, F.; Tam, V. C.; Cattan, S.; more...
    Hepatology (2018)

    Fulltext@MSK | Save
  • Cabozantinib in hepatocellular carcinoma - The author's reply
    Journal Article

    Abou-Alfa, G. K.; Borgman-Hagey, A. E.; Kelley, R. K.
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention
    Journal Article

    Lowery, M. A.; Ptashkin, R.; Jordan, E.; Berger, M. F.; Zehir, A.; Capanu, M.; Kemeny, N. E.; O'Reilly, E. M.; El-Dika, I.; Jarnagin, W. R.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Merle, P.; Rimassa, L.; Ryoo, B.; Cicin, I.; Harris, W.; Banu, E.; Sarker, D.; Tan, B.; Van Vlierberghe, H.; Sen, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save